



BETA DRUGS LIMITED

CORRIGENDUM TO THE NOTICE OF THE EXTRA ORDINARY GENERAL MEETING (EGM)

This Corrigendum is being issued in continuation of Extra Ordinary General Meeting (EGM) notice dated 19th October, 2024 scheduled to be held on Tuesday, 12th November, 2024 at 10.30 AM. IST at registered office of the company situated at Village Nandpur, Lodhimajra Road, Baddi Distt Solan, H.P - 174101. The notice of EGM was dispatched to the shareholders of the Company on 19th October, 2024 electronically & by courier in due compliance with the provisions of the Companies Act, 2013, as amended, and the rules made thereunder (the "Companies Act"), read with circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India ("SEBI"), to transact the business stated therein.

This Corrigendum to the EGM Notice ("Corrigendum") is issued in respect of the following point 1,8,9 &13 of the Explanatory Statement to the EGM Notice under "Item No. 2", to provide certain clarifications pursuant to the suggestions / comments received from National Stock Exchange of India Limited:-

1. In the explanatory statement "Item No. 2", point 1 should be read as follows:

1. Object of the preferential issue of equity shares:

Subject to applicable law, the Company shall utilize the proceeds from the preferential issue for funding capital investment or expenditure requirements of the Company and its subsidiaries (including, by way of investment in its subsidiaries) and other general corporate purposes. The Company will use the Subscription Amount for the following purposes:

#	Use of Funds	Estimated Amount (INR cr)	Timeline
1	Capital Expenditure and Capital Investment (Manufacturing/ R&D capabilities)	72	Within 24 months from the date of allotment of CCDs
2	Geographic expansion (Organic/ Inorganic)	20	
3	General Corporate	25	
	Total	117	

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com

The fund requirement and the proposed utilization schedule are based on management estimates, market conditions, business needs and other commercial and technical factors, and the actual deployment of funds at each stage will depend on a number of factors such as financial, market and sectoral conditions, business performance and strategy, and other external factors (such as competitive environment, pandemic and related government requirements, employment and disposable income levels, demographic trends, technological changes, changing customer preferences and increasing regulations or changes in government policies), which may not be within the control of the Company and may result in modifications to the proposed schedule for utilization of the net proceeds at the discretion of the Board, subject to compliance with applicable laws.

Pending utilization of the proceeds from the Preferential Issue, the Company may invest such proceeds in money/debt market instruments (including mutual funds and liquid funds), deposits in scheduled commercial banks, or any other avenues as permitted under applicable laws.

Further it is confirmed that company will not invest in capital eroding and high risk taking instruments and all other investment shall be done in compliance with the applicable laws.

2. In the explanatory statement “Item No. 2”, point 8 should be read as follows:

8. Identity the Proposed Allottee and the percentage of post preferential issue capital that may be held by them:

To meet the object of the issue, below Proposed Allottee, has shown its intent to subscribe to Equity Shares and CCDs of the Company.

Name of the Proposed Allottees	Category	Pre issue Shareholding		No. of equity shares to be allotted	No. of CCD shares to be allotted	Post issue Shareholding	
		Number	% of shares			Number	% of shares
Healthquad Fund II (a scheme under Healthquad Trust II)	Non-promoter	0	0.00%	70	4,53,623	4,53,693	4.40%
Inti Capital VCC - Inti Capital I	Non-promoter	0	0.00%	30	2,11,691	2,11,721	2.05%
Generational Capital Breakout Fund 1	Non-promoter	14,000	0.15%	0	42,337	56,337	0.55%

3. In the explanatory statement “Item No. 2”, point 9 should be read as follows:

9. Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and/or who ultimately control the proposed allottees, the percentage of post preferential issue capital that may be held by them and change in control, if any, in the issuer consequent to the preferential allotment

Name of the Proposed Allottees	Pre issue Shareholding		Post issue Shareholding		Details of Ultimate Beneficial Owners
	Number	% of shares	Number	% of shares	
Healthquad Fund II (a scheme under Healthquad Trust II)	0	0.0%	4,53,693	4.40%	Charles Antoine Janssen
Inti Capital VCC - Inti Capital I	0	0.0%	2,11,721	2.05%	Raunaq Chamdia
Generational Capital Breakout Fund 1	14,000	0.15%	56,337	0.55%	Satwik Jain

4. In the explanatory statement “Item No. 2”, point 13 should be read as follows:

13. Re-computation of Issue Price:

Since the Company’s equity shares are frequently traded and have been listed on a recognized Stock Exchange for more than 90 trading days prior to the Relevant Date, there is no need for the Company to re-compute the price of equity shares to be issued on preferential basis.

However as per regulation 163 (1) (g) & (h) if it is required to re-compute the price of the specified securities in terms of the provision of these regulations, same will be re-computed and if the amount payable on account of the re-computation of price is not paid within the time stipulated in these regulations, the specified securities shall continue to be locked- in till the time such amount is paid by the allottees.

Members are requested to kindly take note of the aforesaid amendments in the notice and the corresponding corrections before casting their votes.

The Corrigendum to the EGM Notice shall form an integral part of the EGM Notice which has already been circulated to the Members of Company and on and from the date hereof, the EGM Notice shall always be read in conjunction with this Corrigendum. This Corrigendum will also be made available on website of the stock exchange i.e., NSE i.e., www.nseindia.com and on the website of the Company on www.betadrugslimited.com. All other contents of the EGM Notice, save and except as modified or supplemented by the Corrigendum, shall remain unchanged.

By Order of the Directors

Place: Baddi
Date: 28.10.2024

sd/-
Ms. Rajni Brar
Company Secretary